Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone

Recruiting Phase 2 Interventional Study
Hypogonadism, Male Fatigue Syndrome, Chronic
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 54
Sex
Male
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
240 (estimated)
Sponsor
Seattle Institute for Biomedical and Clinical Research · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in yo…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Cancer survivors who have received chemotherapy and/or radiation therapy for their cancer and are now in remission for at least one year * Non-hormone-dependent cancer, including most solid tumors, lymphomas and leukemias * Age: 18-54 years * Serum testosterone, measured by ma…
Contacts

Jose M Garcia, MD, PhD

206 764 2984

jg77@uw.edu

CONTACT